SecBot SecBot
8-K/A ·Filed Nov 10, 2026

ALZN

Alzamend Neuro, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed7d 1h ago SEC0001214659-26-013930
8-K with no item list reported
Actionable Insight ▼ Bearish

Monitor the registration statement filing and effectiveness timeline; failure triggers 2% monthly penalties. The second tranche closing and stockholder approval vote (due within 75 days) are key catalysts. The variable conversion price at a deep discount to market creates persistent overhang.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$1.31
T+0 close · Nov 10, 2026 · via day close
Latest settled
−0.76%
T+1 · $1.30
Vs SPY
−0.41%
α at T+1
Next horizon
T+5
in 13h
  1. T+0 · Nov 11 $1.31entry
  2. T+1 · 5d ago −0.76%α −0.41% · $1.30
  3. T+4 · todayOpen
  4. T+5 · in 13h Pending
  5. T+20 · in 23d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alzamend Neuro filed an 8-K/A amending its July 2026 securities purchase agreement with Ault Lending, LLC. The total financing was reduced from $25M to $10M, with $7.5M already closed in July and a second $2.5M tranche to close upon SEC effectiveness of a resale registration statement. The Series D preferred shares carry a conversion price floor of $0.2668 and a variable conversion discount of 80% of the lowest 5-day closing bid, creating potentially massive dilution relative to the company's $7M market cap.

Key Facts

  • Original $25M financing reduced to $10M; $7.5M already sold in July 2026, $2.5M second tranche pending.
  • Second tranche closing conditioned on SEC effectiveness of registration statement and stock price above $0.2668 floor.
  • Conversion price is the greater of $0.2668 or 80% of the lowest 5-day closing bid, capped at $2.00.
  • Company must seek stockholder approval for conversion shares exceeding 19.99% of outstanding common stock.
  • Registration statement must be filed by November 17, 2026; failure triggers 2% monthly liquidated damages (max 15%).
  • Purchaser has right of first refusal and 33.33% participation right in future equity offerings for 3 years.
  • Most-favored-nation clause: any better terms in future financings automatically apply to this purchaser.
  • Company market cap is $7M; potential conversion shares could massively dilute existing holders.

Financial Impact

Up to $10M in Series D preferred sold; $7.5M already received. Conversion shares could exceed 19.99% of outstanding common, requiring stockholder approval. Dilution from full conversion at $0.2668 floor would be enormous relative to $7M market cap.

dilutioncapital_structureshare_count

Risk Factors

  • Massive potential dilution from conversion of Series D preferred at deeply discounted variable price.
  • Registration statement delays could trigger escalating cash penalties.
  • Stockholder approval may not be obtained, limiting conversion and voting rights.
  • Company has only $7M market cap; additional $2.5M tranche and $10M additional investment right could overwhelm equity base.
  • Most-favored-nation and participation rights give purchaser significant control over future financings.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001214659-26-013930
Exhibit: ex10_2.htm0001214659-26-013930
Exhibit: ex3_1.htm0001214659-26-013930
Document: o11102668ka1.htm0001214659-26-013930

Track record

6 reports on ALZN

Performance horizon
Filters
  1. Nov 17, 2026today S-3 Bearish 7/10 Entry $1.11 Now $1.13 −1.80% settles Nov 19
  2. Nov 17, 2026today 8-K Bearish 6/10 Entry $1.14 Now $1.13 +0.88% settles Nov 19
  3. Nov 10, 20267d ago 8-K/A Bearish 7/10 Viewing Entry $1.31 to $1.30 Now $1.13 +13.74% ▲ +0.76% +0.41% vs SPY
  4. Sep 29, 20267w ago 8-K Neutral 3/10 Entry $1.82 to $1.73 Now $1.13 −37.91% ▼ −4.95% −4.74% vs SPY
  5. Aug 4, 202614w ago 3 Neutral 2/10 Entry $1.43 to $1.38 Now $1.13 −20.98% ▼ −3.50% −3.34% vs SPY
  6. Feb 26, 202637w ago DEFA14A Neutral 4/10 Entry $2.01 to $2.01 Now $1.13 −43.78% · 0.00% −0.06% vs SPY
Showing 6 of 6

US Market Status

Market Closed · Opens Wed (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 10, 2026